HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Exits Consumer Health With Haleon Launch

Executive Summary

The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.

You may also be interested in...



Nicorette Gum Package Front In US Adds Initial, Zyrtec Labeling Gets ‘New’ For Limited Time

Front panels for 34 SKUs for Haleon’s Nicorette 2- and 4-mg gum in approved to include a superimposed letter N; labeling approved for seven SKUs for Kenvue’s Zyrtec Allergy 5- and 10-mg tablets to include “new” for six months.

J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other

Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.

Relief For Excedrin Migraine, Green For Package

Approved changes are for primary display panel on immediate container and outer carton for total of eight packages, from 24- to 300-count, and include making the brand name Excedrin Migraine Relief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel